Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a chronic, immune-mediated cholestatic liver disease that often progresses to secondary biliary cirrhosis and end-stage liver disease. Short of liver transplantation (LT), there is no effective treatment for PSC. PSC accounts for approximately 5% of total adult LTs in the US and is currently the fifth most common indication for LT. Patient and graft survival for PSC is among the highest for all indications for LT. The main factors that impact outcomes after LT for PSC include biliary strictures, rejection, and recurrence of PSC. Recurrent PSC (rPSC) develops in 20% of LT recipients within 5 years of LT and is associated with negative patient and graft survival. LT is a viable option for recipients who develop rPSC and progress to graft failure.

Original languageEnglish (US)
Pages (from-to)305-313
Number of pages9
JournalSeminars in Liver Disease
Volume37
Issue number4
DOIs
StatePublished - Nov 1 2017

Fingerprint

Sclerosing Cholangitis
Liver Transplantation
Graft Survival
End Stage Liver Disease
Biliary Liver Cirrhosis
Liver Diseases
Pathologic Constriction
Transplants
Recurrence

Keywords

  • liver transplantation
  • outcomes
  • primary sclerosing cholangitis
  • recurrence

ASJC Scopus subject areas

  • Hepatology

Cite this

Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis. / Martin, Eric; Levy, Cynthia.

In: Seminars in Liver Disease, Vol. 37, No. 4, 01.11.2017, p. 305-313.

Research output: Contribution to journalArticle

@article{92999db753da4b148906640cfde00c15,
title = "Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis",
abstract = "Primary sclerosing cholangitis (PSC) is a chronic, immune-mediated cholestatic liver disease that often progresses to secondary biliary cirrhosis and end-stage liver disease. Short of liver transplantation (LT), there is no effective treatment for PSC. PSC accounts for approximately 5{\%} of total adult LTs in the US and is currently the fifth most common indication for LT. Patient and graft survival for PSC is among the highest for all indications for LT. The main factors that impact outcomes after LT for PSC include biliary strictures, rejection, and recurrence of PSC. Recurrent PSC (rPSC) develops in 20{\%} of LT recipients within 5 years of LT and is associated with negative patient and graft survival. LT is a viable option for recipients who develop rPSC and progress to graft failure.",
keywords = "liver transplantation, outcomes, primary sclerosing cholangitis, recurrence",
author = "Eric Martin and Cynthia Levy",
year = "2017",
month = "11",
day = "1",
doi = "10.1055/s-0037-1608655",
language = "English (US)",
volume = "37",
pages = "305--313",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis

AU - Martin, Eric

AU - Levy, Cynthia

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Primary sclerosing cholangitis (PSC) is a chronic, immune-mediated cholestatic liver disease that often progresses to secondary biliary cirrhosis and end-stage liver disease. Short of liver transplantation (LT), there is no effective treatment for PSC. PSC accounts for approximately 5% of total adult LTs in the US and is currently the fifth most common indication for LT. Patient and graft survival for PSC is among the highest for all indications for LT. The main factors that impact outcomes after LT for PSC include biliary strictures, rejection, and recurrence of PSC. Recurrent PSC (rPSC) develops in 20% of LT recipients within 5 years of LT and is associated with negative patient and graft survival. LT is a viable option for recipients who develop rPSC and progress to graft failure.

AB - Primary sclerosing cholangitis (PSC) is a chronic, immune-mediated cholestatic liver disease that often progresses to secondary biliary cirrhosis and end-stage liver disease. Short of liver transplantation (LT), there is no effective treatment for PSC. PSC accounts for approximately 5% of total adult LTs in the US and is currently the fifth most common indication for LT. Patient and graft survival for PSC is among the highest for all indications for LT. The main factors that impact outcomes after LT for PSC include biliary strictures, rejection, and recurrence of PSC. Recurrent PSC (rPSC) develops in 20% of LT recipients within 5 years of LT and is associated with negative patient and graft survival. LT is a viable option for recipients who develop rPSC and progress to graft failure.

KW - liver transplantation

KW - outcomes

KW - primary sclerosing cholangitis

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=85039160387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039160387&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1608655

DO - 10.1055/s-0037-1608655

M3 - Article

C2 - 29272893

AN - SCOPUS:85039160387

VL - 37

SP - 305

EP - 313

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 4

ER -